Anemia And Other Blood Disorder Drugs Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the anemia and other blood disorder drugs market grown in recent years?
The market for anemia and other blood disorder medications has seen robust growth in the past few years. It’s projected to increase from $11.61 billion in 2024 to $12.38 billion in 2025, boasting a compound annual growth rate (CAGR) of 6.6%. Factors contributing to this historic growth include the prevalence of disease, worldwide health initiatives, an aging population, innovations in pharmaceuticals, and heightened patient awareness.
How is the anemia and other blood disorder drugs market size expected to evolve during the forecast period?
The market size of drugs concerning anemia and other blood disorders is projected to experience significant growth within the next few years. It’s projected to increase to a worth of $16.09 billion in 2029, with a 6.8% compound annual growth rate (CAGR). The growth predicted in this period can be attributed to factors such as emerging markets, global demographics, and economic elements. Major trends contributing to this growth over the forecast timeframe include advances in research and development, improvements in technology, biologically based and targeted therapies, gene therapies, the implementation of telemedicine and remote monitoring, orphan drug classifications, and the occurrence of mergers and acquisitions.
Get your anemia and other blood disorder drugs market report here!
https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp
Which key drivers are propelling the anemia and other blood disorder drugs market’s growth?
The rise in anemia cases worldwide, largely due to unhealthy lifestyles, altered eating habits, and heightened stress levels, is a significant stimulus for the market. Anemia has become the most common ailment in individuals over the age of 65, with an approximate prevalence rate of 17%. According to the World Bank, anemia ranks as the 8th primary disease amongst women and the younger population. The escalating prevalence of anemia fuels the anemia and other blood disorder drugs market.
What are the market segments in the anemia and other blood disorder drugs industry?
The anemia and other blood disorder drugs market covered in this report is segmented –
1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia
2) By Route of Administration: Oral, Injectable
3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy
Subsegments:
1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods
2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion
3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs
4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp
Which leading companies are shaping the growth of the anemia and other blood disorder drugs market?
Major companies operating in the anemia and other blood disorder drugs market include Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., GlycoMimetics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Pieris Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., Allergan U.S. Inc., Meda Consumer Healthcare Inc., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Galenica Ltd., Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., uniQure N.V., Rubius Therapeutics Inc., BioMarin Pharmaceutical Inc., Grifols S.A., Orchard Therapeutics plc
What key trends are currently impacting the anemia and other blood disorder drugs market’s development?
Firms within the anemia and other blood disorder drugs industry are forming alliances with governmental bodies to share knowledge, technology, and expenses in the creation and launch of a particular type of drug. These cooperations can also offer support to these companies when licenses are about to expire or when they face stringent regulatory situations. As an illustration, Disc Medicine publicized its partnership with the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI) in March 2023. The partnership is centered on the Phase 1/2 and Phase 2 clinical trials of biopterin for Diamond-Blackfan Anemia (DBA) patients and treatment of iron deficiency anemia in adult patients. The NIH, under a cooperative research and development agreement (CRADA), will carry out and finance these studies.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2465
Which geographic areas are influencing the growth of the anemia and other blood disorder drugs market?
North America was the largest region in the anemia and other blood disorder drugs market in 2023. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
COVID-19 Drug Associated APIs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/covid19-drug-associated-api-global-market-report
Hospital Acquired Infections Testing Kits Global Market Report 2024
Liposomal Drug Delivery Devices Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
